TABLE 2.
Sample characteristics by the presence of diabetes
| Total n = 81,907, % | No diabetes n = 34,314, % | Diabetes at baseline n = 46,035, % | Diabetes during follow-up n = 1558, % | p | |
|---|---|---|---|---|---|
| Age (y) | 63.0 (8.9) | 62.0 (9.0) | 63.9 (8.7) | 58.6 (8.1) | <0.001 |
| Male sex | 97.2 | 97.0 | 97.3 | 97.1 | 0.02 |
| Race and ethnicity | <0.001 | ||||
| White | 61.1 | 62.1 | 60.4 | 60.6 | |
| Black | 18.8 | 18.6 | 18.9 | 18.7 | |
| Hispanic | 8.4 | 7.4 | 9.2 | 8.5 | |
| Asian | 1.2 | 1.2 | 1.3 | 1.5 | |
| Native American | 1.2 | 1.2 | 1.2 | 2.2 | |
| Other | 3.8 | 4.2 | 3.6 | 2.6 | |
| Unknown | 5.4 | 5.4 | 5.4 | 5.9 | |
| Etiology of cirrhosis | <0.001 | ||||
| Alcohol | 32.1 | 34.4 | 30.3 | 36.3 | |
| Alcohol/HCV | 21.4 | 24.9 | 18.8 | 24.7 | |
| HCV | 20.9 | 23.8 | 18.7 | 20.5 | |
| MASLD | 21.9 | 12.5 | 29.2 | 13.0 | |
| HBV | 0.9 | 1.0 | 0.9 | 0.8 | |
| Other | 2.7 | 3.4 | 2.1 | 4.8 | |
| Unknown | 0.1 | 0.1 | 0.0 | 0.0 | |
| HCV status | <0.001 | ||||
| Never HCV-infected | 57.7 | 51.3 | 62.5 | 54.9 | |
| Cleared HCV | 26.1 | 31.2 | 22.0 | 33.3 | |
| Persistent HCV | 16.3 | 17.5 | 15.5 | 11.9 | |
| Unknown | 0.1 | 0.1 | 0.0 | 0.0 | |
| AUDIT-C | <0.001 | ||||
| Low risk | 71.0 | 63.6 | 76.7 | 64.9 | |
| Moderate risk | 9.5 | 11.9 | 7.6 | 10.5 | |
| High risk | 4.2 | 5.4 | 3.3 | 6.1 | |
| Severe risk | 11.9 | 15.7 | 9.0 | 15.7 | |
| Unknown | 3.4 | 3.5 | 3.4 | 3.1 | |
| CTP class | <0.001 | ||||
| A | 61.1 | 44.9 | 70.4 | 79.3 | |
| B | 32.3 | 44.7 | 26.1 | 18.1 | |
| C | 6.6 | 10.4 | 3.5 | 2.7 | |
| Statin use | 38.1 | 23.0 | 50.0 | 20.2 | <0.001 |
| Years of follow-up | 4.6 (3.4) | 4.8 (3.5) | 4.5 (3.4) | 6.7 (3.7) | <0.001 |
| HCC incidence (per 100 person-years) | 2.11 | 1.96 | 2.18 | 2.99 | <0.001 |
| Incident HCC | 9.8 | 9.3 | 9.8 | 20.2 | <0.001 |
| Deceased | 50.3 | 46.0 | 54.1 | 32.2 | <0.001 |
Note: Continuous variables age and years of follow-up are presented as mean (SD).
Abbreviations: AUDIT-C, Alcohol Use Disorders Identification Test-Consumption; CTP Child-Turcotte-Pugh; MASLD, metabolic dysfunction–associated steatotic liver disease.